Cure8 news brief
Routinely collected healthcare data can reveal how Crohn’s disease is managed and experienced in everyday practice, helping fill gaps left by clinical trials. A broader, data-driven measure of disease burden could better capture the real-life impact of Crohn’s disease on patients.
Clinicians, multidisciplinary teams, researchers using real-world data, and patients/advocates interested in Crohn’s disease measurement and outcomes.
The author emphasizes that routinely collected data (electronic records, administrative datasets, linked sources) can capture long-term, real-world patterns of disease, treatment, healthcare use, and outcomes that complement clinical trials. Data quality, coding, missingness, and governance are highlighted as critical considerations.
The talk also focuses on measuring multidimensional disease burden in Crohn’s disease—beyond single measures of inflammation or symptoms—to include functional, psychological, treatment, and healthcare-utilisation components and the challenges of combining them into a robust, patient-meaningful metric.
This is an interview previewing talks at a conference (UEG Week) and discussing research aims and methodological issues; it does not report new clinical trial results or validated measurement tools.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Wearable-derived digital biomarkers aim to detect flares earlier and reduce reliance on questionnaires; patients' acceptance is essential for real-world use. High reported willingness suggests patient-centered...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Real‑world studies of ustekinumab help patients and clinicians understand how the drug performs outside clinical trials, including effectiveness for steroid‑free remission and use across different UK care settings.
